Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free MAAQ Stock Alerts

Mana Capital Acquisition (MAAQ) Competitors

$1.61 +0.10 (+6.62%)
As of 05/22/2026
Compare

MAAQ vs. XLO, ATYR, MGX, ESLA, and IXHL

Should you buy Mana Capital Acquisition stock or one of its competitors? MarketBeat compares Mana Capital Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mana Capital Acquisition include Xilio Therapeutics (XLO), aTyr Pharma (ATYR), Metagenomi (MGX), Estrella Immunopharma (ESLA), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does Mana Capital Acquisition compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mana Capital Acquisition has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Mana Capital Acquisition's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-58.52% -151.42% -27.61%
Mana Capital Acquisition N/A N/A N/A

In the previous week, Xilio Therapeutics' average media sentiment score of 1.00 beat Mana Capital Acquisition's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Xilio Therapeutics Positive
Mana Capital Acquisition Neutral

Xilio Therapeutics presently has a consensus price target of $28.00, suggesting a potential upside of 239.39%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Mana Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Mana Capital Acquisition has lower revenue, but higher earnings than Xilio Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.13-$35.04M-$3.55N/A
Mana Capital AcquisitionN/AN/AN/AN/AN/A

Summary

Xilio Therapeutics beats Mana Capital Acquisition on 6 of the 10 factors compared between the two stocks.

How does Mana Capital Acquisition compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mana Capital Acquisition's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
aTyr PharmaN/A -100.14% -73.55%
Mana Capital Acquisition N/A N/A N/A

In the previous week, aTyr Pharma had 4 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 4 mentions for aTyr Pharma and 0 mentions for Mana Capital Acquisition. aTyr Pharma's average media sentiment score of 0.50 beat Mana Capital Acquisition's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media.

Company Overall Sentiment
aTyr Pharma Positive
Mana Capital Acquisition Neutral

aTyr Pharma presently has a consensus target price of $25.67, indicating a potential upside of 5,138.10%. Given aTyr Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe aTyr Pharma is more favorable than Mana Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Mana Capital Acquisition has lower revenue, but higher earnings than aTyr Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
aTyr Pharma$190K252.87-$74.12M-$0.73N/A
Mana Capital AcquisitionN/AN/AN/AN/AN/A

Summary

aTyr Pharma beats Mana Capital Acquisition on 8 of the 11 factors compared between the two stocks.

How does Mana Capital Acquisition compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Metagenomi's average media sentiment score of 0.00 equaled Mana Capital Acquisition'saverage media sentiment score.

Company Overall Sentiment
Metagenomi Neutral
Mana Capital Acquisition Neutral

68.4% of Mana Capital Acquisition shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mana Capital Acquisition has lower revenue, but higher earnings than Metagenomi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$25.21M2.02-$87.87M-$2.30N/A
Mana Capital AcquisitionN/AN/AN/AN/AN/A

Metagenomi presently has a consensus target price of $9.00, suggesting a potential upside of 566.67%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metagenomi is more favorable than Mana Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Mana Capital Acquisition has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Mana Capital Acquisition's return on equity of 0.00% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-384.61% -51.23% -36.62%
Mana Capital Acquisition N/A N/A N/A

Summary

Metagenomi beats Mana Capital Acquisition on 6 of the 10 factors compared between the two stocks.

How does Mana Capital Acquisition compare to Estrella Immunopharma?

Mana Capital Acquisition (NASDAQ:MAAQ) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Mana Capital AcquisitionN/A N/A N/A
Estrella Immunopharma N/A N/A -397.36%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mana Capital AcquisitionN/AN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/A-$13.06M-$0.34N/A

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 589.66%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Mana Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Estrella Immunopharma had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Mana Capital Acquisition. Estrella Immunopharma's average media sentiment score of 3.00 beat Mana Capital Acquisition's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Mana Capital Acquisition Neutral
Estrella Immunopharma Very Positive

68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Estrella Immunopharma beats Mana Capital Acquisition on 6 of the 8 factors compared between the two stocks.

How does Mana Capital Acquisition compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Mana Capital Acquisition has lower revenue, but higher earnings than Incannex Healthcare.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K468.16-$46.88M-$1.55N/A
Mana Capital AcquisitionN/AN/AN/AN/AN/A

Mana Capital Acquisition's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -81.01% -76.11%
Mana Capital Acquisition N/A N/A N/A

In the previous week, Incannex Healthcare had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Incannex Healthcare and 0 mentions for Mana Capital Acquisition. Incannex Healthcare's average media sentiment score of 0.63 beat Mana Capital Acquisition's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Incannex Healthcare Positive
Mana Capital Acquisition Neutral

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Incannex Healthcare beats Mana Capital Acquisition on 5 of the 8 factors compared between the two stocks.

Get Mana Capital Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MAAQ vs. The Competition

Export
MetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$13.08M$1.23B$4.26B$12.34B
Dividend YieldN/AN/A5.93%5.28%
P/E RatioN/AN/A21.9025.66
Price / SalesN/A294.76180.5986.31
Price / CashN/A730.6955.6856.67
Price / BookN/A77.8534.857.14
Net IncomeN/A-$18.48M$112.32M$335.98M
7 Day Performance15.83%9.31%3.54%4.11%
1 Month Performance-11.54%21.44%3.58%2.52%
1 Year Performance-59.24%-59.24%15.80%35.04%

Mana Capital Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MAAQ
Mana Capital Acquisition
N/A$1.61
+6.6%		N/A-59.2%$13.08MN/AN/A1
XLO
Xilio Therapeutics
3.3073 of 5 stars		$8.15
-2.5%		$28.00
+243.6%		-33.3%$50.02M$43.77MN/A70
ATYR
aTyr Pharma
2.231 of 5 stars		$0.52
+3.1%		$25.67
+4,840.6%		-86.9%$49.42M$190KN/A53
MGX
Metagenomi
2.4423 of 5 stars		$1.27
-3.1%		$9.00
+608.7%		-16.7%$49.32M$25.21MN/A236
ESLA
Estrella Immunopharma
3.3306 of 5 stars		$1.12
+0.9%		$8.00
+614.3%		+11.5%$47.36MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MAAQ) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel